IMUNON, Inc. has announced promising results from its Phase 2 OVATION 2 Study involving its investigational immunotherapy, IMNN-001, for advanced ovarian cancer. Patients receiving the new treatment in combination with standard chemotherapy experienced a median overall survival increase from 11.1 months to 13 months compared to those on chemotherapy alone, as reported by the company.
Further, over one third of the patients in the IMNN-001 group survived more than 36 months, with approximately 10% making it past the 48-month mark. IMNN-001 also demonstrated a favorable safety profile, with no incidents of cytokine release syndrome or serious immune-related adverse effects noted during the study.
With these encouraging outcomes, IMUNON is moving forward with the Phase 3 OVATION 3 study, expected to start in the first quarter of 2025. This next phase aims to further assess the efficacy and safety of IMNN-001, building on the positive data from the Phase 2 trial.